← Back to RLMD

Relmada Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 06/08/2026Mar 2026Filed 06/08/2026Sep 2025Filed 13/11/2025Jun 2025Filed 06/08/2026Mar 2025Filed 06/08/2026Sep 2024Filed 13/11/2025Jun 2024Filed 13/11/2025Mar 2024Filed 13/11/2025
−$13−$19−$10−$9.9−$18−$22−$18−$22
−$0.11−$0.22−$0.30−$0.30−$0.58−$0.72−$0.59−$0.72
11287333330303030

Trend

Net income

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.